deltatrials
Completed PHASE1/PHASE2 NCT00002558

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors

PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Extragonadal Germ Cell Tumor Ovarian Cancer Testicular Germ Cell Tumor
Interventions carboplatin etoposide filgrastim ifosfamide paclitaxel peripheral blood stem cell transplantation
Updated 6 times since 2017 Last updated: Apr 11, 2016 Started: Jan 31, 1994 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

Listed as NCT00002558, this PHASE1/PHASE2 trial focuses on Extragonadal Germ Cell Tumor and Ovarian Cancer and remains completed. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 6 times since 1994, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Jan 1994

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • National Cancer Institute (NCI)
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States